Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A275935-1mg | 1mg | In stock | $28.90 | |
A275935-5mg | 5mg | In stock | $117.90 | |
A275935-10mg | 10mg | In stock | $206.90 | |
A275935-25mg | 25mg | In stock | $465.90 | |
A275935-50mg | 50mg | In stock | $800.90 | |
A275935-100mg | 100mg | In stock | $1,335.90 |
Potent, selective, ATP competitive JNK inhibitor. Cell-permeable.
Synonyms | VNA98715 | HY-11010 | Q27163222 | 2-(4-dimethylaminophenyl)-1h-benzimidazole | 2-Benzothiazoleacetonitrile, alpha-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)- | benzoic acid (4-oxo-cyclohexyl) ester | (2s)-1,3-Benzothiazol-2-Yl{2-[(2-Pyridin-3-Ylethyl |
---|---|
Specifications & Purity | Moligand™, ≥95% |
Biochemical and Physiological Mechanisms | Potent, selective, ATP competitive JNK inhibitor (IC 50 values are 150, 220 and 70 nM for hJNK1,2 and 3 respectively). Reduces cell adhesion and migration in cancer cells. anti-ischemic effects in vivo . |
Storage Temp | Store at -20°C,Desiccated |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of mitogen-activated protein kinase 10 |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. product description: A cell-permeable pyrimidinyl compound that displays anti-inflammatory properties. Acts as a potent, reversible, and ATP-competitive inhibitor of c-Jun N-terminal kinase (JNK, IC50 = 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3, respectively) with a 10- to 100-fold greater selectivity over a panel of 25 other commonly studied kinases (IC50 typically in the range of 1-10 µM or no effect at 10 µM). Its in vivo efficacy has been demonstrated in gerbils, mice, and rats via oral, i.v., or i.p. administration. Biochemical mechanism: Cell permeable: yes Product competes with ATP. Primary Target hJNK 1, hJNK 2, hJNK 3 Reversible: yes Target IC50: 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3, respectively |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 2-(1,3-benzothiazol-2-yl)-2-[2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile |
---|---|
INCHI | InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,15H,7,10H2,(H,23,24,26) |
InChi Key | RCYPVQCPYKNSTG-UHFFFAOYSA-N |
Canonical SMILES | C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4 |
Isomeric SMILES | C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4 |
PubChem CID | 10109823 |
Molecular Weight | 372.45 |
PubChem CID | 11422035 |
---|---|
ChEMBL Ligand | CHEMBL191384 |
CAS Registry No. | 345987-15-7 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2318670 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318673 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318688 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318823 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318880 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318885 | Certificate of Analysis | Dec 21, 2023 | A275935 |
Solubility | Soluble in DMSO to 25 mM |
---|
1. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D et al.. (2005) Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.. J Med Chem, 48 (14): (4596-607). [PMID:15999997] |
2. Ivshina MP et al.. (2022) CPEB1 regulates the inflammatory immune response, phagocytosis, and alternative polyadenylation in microglia.. Glia, 70 (10): (1850-1863). [PMID:35635122] |